C. Hunt

发表

Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase™

William M. Lee, E. Bjornsson, R. Andrade, 2010, Drug safety.

Drug-induced liver injury following positive drug rechallenge.

N. Yuen, C. Hunt, J. Walsh, 2009, Regulatory toxicology and pharmacology : RTP.

Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug‐induced liver injury: A systematic review

C. Hunt, 2010, Hepatology.

Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.

Chun-Fang Xu, C. Hunt, C. Spraggs, 2013, Pharmacogenomics.

A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data

Jeffery L. Painter, Xiwu Lin, C. Hunt, 2013, Pharmacoepidemiology and drug safety.

Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient.

M. Washington, C. Hunt, P. Clavien, 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Hepatitis C

C. Hunt, J. Hamilton, A. Sharara, 1996, Annals of Internal Medicine.

Regulation of rat hepatic cytochrome P450IIE1 in primary monolayer hepatocyte culture.

C. Hunt, S. Wright, P. Guzelian, 1991, Xenobiotica; the fate of foreign compounds in biological systems.

Validation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations

Jeffery L. Painter, Xiwu Lin, C. Hunt, 2012, Drug Safety.

Chronic Hepatitis C on Health-Related Quality of Life

C. Hunt, J. Dominitz, B. Waters, 1997 .

Lapatinib‐Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes

C. Dollery, C. Hunt, C. Spraggs, 2012, Clinical pharmacology and therapeutics.

Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations.

Jeffery L. Painter, Xiwu Lin, C. Hunt, 2012, Drug safety.

Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1.

R. O’Neill, C. Hunt, A. Power, 2009, Pharmacogenomics.

Evaluation of a workplace hemochromatosis screening program.

C. Hunt, G. Stave, J. Mignogna, 1999, American journal of preventive medicine.

Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial

H. Bonkovsky, C. Hunt, B. Bacon, 2000, Hepatology.

Lamivudine therapy of chronic hepatitis B.

C. Hunt, M. Rubin, N. Brown, 1999, Advances in experimental medicine and biology.

Hepatitis C in pregnancy

C. Hunt, A. Sharara, K. Carson, 1997, Obstetrics and gynecology.

The evaluation of drug rechallenge: the casopitant Phase III program.

C. Hunt, M. Russo, Julie I. Papay, 2010, Regulatory toxicology and pharmacology : RTP.

Ayako Suzuki, A. Suzuki, N. Yuen, 2014, Regulatory toxicology and pharmacology : RTP.

Hepatic cytochrome P-4503A (CYP3A) activity in the elderly

C. Hunt, G. Stave, Joanne A. P. Wilson, 1992, Mechanisms of Ageing and Development.

Effect of normal aging on the activity of human hepatic cytochrome P450IIE1.

C. Hunt, G. Stave, S. Strater, 1990, Biochemical pharmacology.

Alanine Aminotransferase Results Differ by Analyzer Manufacturer in a National Integrated Health Setting, 2012-2017.

C. Hunt, L. Beste, Leslie L. Taylor, 2019, Archives of pathology & laboratory medicine.

Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?

G. Su, C. Hunt, M. Fuchs, 2019, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

Effects of inhibition and induction of cytochrome P-450 isozymes on hyperoxic lung injury in rats.

C. Piantadosi, C. Hunt, N. Todd, 1992, American journal of respiratory cell and molecular biology.

Monitoring liver safety in drug development: the GSK experience.

C. Dollery, C. Hunt, T. Gibbs, 2007, Regulatory toxicology and pharmacology : RTP.

Clinical and pathological variability of infection by enterohaemorrhagic (Vero cytotoxin producing) Escherichia coli.

C. Hunt, J. Harvey, T. Reid, 1989, Journal of clinical pathology.

Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans

C. Hunt, Christina D. Williams, T. Redding, 2022, Journal of General Internal Medicine.

Associations Between Gastrointestinal Symptoms and COVID-19 Severity Outcomes Based on a Propensity Score–Weighted Analysis of a Nationwide Cohort

Alese E. Halvorson, E. Siew, A. Hung, 2022, Gastro Hep Advances.

Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease.

D. Webb, C. Hunt, M. Irizarry, 2012, Regulatory toxicology and pharmacology : RTP.

Pharmacogenetic variants and risk of remdesivir‐associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID‐19

S. Luoh, C. Robinson-Cohen, C. Hunt, 2022, Clinical and Translational Science.

Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients.

C. Hunt, Ching-lung Lai, G. Dusheiko, 1998 .

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

Ching-Lung Lai, E. Schiff, C. Hunt, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Characterizing phenotypes and outcomes of drug‐associated liver injury using electronic medical record data

A. Suzuki, C. Hunt, Julie I. Papay, 2013, Pharmacoepidemiology and drug safety.

Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients

M. Washington, C. Hunt, W. Chey, 2001, American Journal of Gastroenterology.

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria

C. Hunt, A. Mangel, G. Kapke, 1999, American Journal of Gastroenterology.

Clinical relevance of hepatitis B viral mutations

C. Hunt, C M Hunt, J M McGill, 2000, Hepatology.

Title Prevalence and clinical correlates of YMDD variants duringlamivudine therapy for patients with chronic hepatitis B

E. Schiff, C. Hunt, N. Leung, 2003 .

Medical Problems Occurring After Orthotopic Liver Transplantation

C. Hunt, K. Carson, 1997, Digestive Diseases and Sciences.

Liver disease in pregnancy.

C. Hunt, A. Sharara, 1999, American Family Physician.

Evidence-Based Liver Chemistry Monitoring in Drug Development

C. Hunt, H. Stirnadel, Julie I. Papay, 2009, Pharmaceutical Medicine.

A pre-marketing ALT signal predicts post-marketing liver safety.

A. Suzuki, N. Yuen, C. Hunt, 2012, Regulatory toxicology and pharmacology : RTP.

Disparity in osmolarity-induced vascular reactivity.

C. Hunt, E. Zakaria, P. Harris, 2005, Journal of the American Society of Nephrology : JASN.

Effect of Interferon-α Treatment of Chronic Hepatitis C on Health-Related Quality of Life

C. Hunt, J. Dominitz, B. Waters, 1997, Digestive Diseases and Sciences.

Effect of age and gender on the activity of human hepatic CYP3A.

C. Hunt, G. Stave, W. R. Westerkam, 1992, Biochemical pharmacology.

Drug rechallenge following drug‐induced liver injury

C. Hunt, Julie I. Papay, A. Regev, 2017, Hepatology.

Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration

A. Suzuki, C. Hunt, C. Moylan, 2018, Digestive Diseases and Sciences.

Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease.

C. Hunt, P. Cotton, A. Sharara, 1996, The American journal of gastroenterology.

Tetracycline-induced bile duct paucity and prolonged cholestasis.

K. Washington, C. Hunt, 1994, Gastroenterology.

Alterations in colonic mucosal vessels in patients with cirrhosis and noncirrhotic portal hypertension.

K. Washington, C. Hunt, L. Lamps, 1998, Human pathology.

Effects of benzo[a]pyrene-coated particles in a bacterial mutagenicity test and on macrophages in culture

C. Hunt, P. Davis, S. Hubbard, 1986 .

Mutagenic Activity of Benzo(a)pyrene-coated Particles

C. Hunt, J. Bridges, S. Hubbard, 1985 .

Background incidence of serum creatinine threshold rises in a predominantly female clinical trial population without underlying renal disease.

C. Hunt, J. Weil, Yanfang Liu, 2010, Regulatory toxicology and pharmacology : RTP.

Preventing Hepatitis B Reactivation During Anti‐CD20 Antibody Treatment in the Veterans Health Administration

A. J. Bullard, Elise A. Stave, C. Hunt, 2018, Hepatology communications.

APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.

S. Luoh, C. Robinson-Cohen, E. Siew, 2022, JAMA internal medicine.

Case Report: Combined Factor IX and XI Deficiency Discovered at Liver Biopsy

C. Hunt, T. Ortel, K. Carson, 1997, Digestive Diseases and Sciences.

Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™.

Ayako Suzuki, A. Suzuki, N. Yuen, 2015, Regulatory toxicology and pharmacology : RTP.

An automated causality assessment algorithm to detect drug‐induced liver injury in electronic medical record data

Stephanie J. Reisinger, C. Hunt, T. Cheetham, 2014, Pharmacoepidemiology and drug safety.

Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.

A. Suzuki, C. Hunt, C. Moylan, 2016, World Journal of Gastroenterology.

Risk factors for biopsy‐proven advanced non‐alcoholic fatty liver disease in the Veterans Health Administration

C. Hunt, C. Moylan, D. Provenzale, 2018, Alimentary pharmacology & therapeutics.

Therapy for spontaneous umbilical hernia rupture.

C. Hunt, A. Maniatis, 1995, The American journal of gastroenterology.

Children's liver chemistries vary with age and gender and require customized pediatric reference ranges.

C. Hunt, N. Galwey, H. Stirnadel-Farrant, 2015, Regulatory toxicology and pharmacology : RTP.

COVID-19-Associated Mortality in US Veterans with and without SARS-CoV-2 Infection

A. Suzuki, C. Hunt, T. Redding, 2021, International journal of environmental research and public health.

Interplay of gender, age and drug properties on reporting frequency of drug‐induced liver injury

Minjun Chen, A. Suzuki, N. Yuen, 2018, Regulatory toxicology and pharmacology : RTP.

Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort

Alese E. Halvorson, E. Siew, A. Suzuki, 2021, Gut.

Editorial: diabetes, obesity and clinical inertia—the recipe for advanced NASH. Authors’ reply

C. Hunt, Y. Patel, 2018, Alimentary pharmacology & therapeutics.

Effect of orthotopic liver transplantation on employment and health status.

C. Hunt, P. Clavien, E. Dowdy, 1996, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration

W. Tong, R. Andrade, C. Hunt, 2022, Drug Safety.

Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury.

A. Suzuki, N. Yuen, C. Hunt, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

G. Su, C. Hunt, M. Turner, 2019 .

Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease.

C. Hunt, H. Stirnadel, J. Weil, 2008, Regulatory toxicology and pharmacology : RTP.

Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.

C. Hunt, S. Landis, S. Shantakumar, 2016, Regulatory toxicology and pharmacology : RTP.

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.

C. Hunt, J. Dominitz, D. M. Williams, 1997, Digestive diseases and sciences.

Identifying and Treating Nonalcoholic Fatty Liver Disease.

G. Su, C. Hunt, M. Turner, 2019, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

Effect of postoperative complications on health and employment following liver transplantation.

C. Camargo, C. Hunt, J. Dominitz, 1998, Clinical transplantation.

Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.

C. Hunt, J. Freston, V. Torres, 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans

Thomas S. Redding, C. Hunt, Andrew D. Thompson, 2022, Journal of General Internal Medicine.

Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.

A. Suzuki, C. Hunt, C. Moylan, 2016 .

Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury

M. Molokhia, E. Bjornsson, P. Watkins, 2011, Clinical pharmacology and therapeutics.

coli . cytotoxin producing ) Escherichia enterohaemorrhagic ( Vero variability of infection by Clinical and pathological

C. Hunt, J. Harvey, T. Reid, 2005 .

Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013.

C. Hunt, S. Duvall, B. Berse, 2016, Military medicine.

Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis

C. Hunt, J. McGill, Diane M. Williams, 1996, Digestive Diseases and Sciences.

Expanding our toolkit to better identify drug‐induced liver injury in electronic medical records

C. Hunt, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase™

William M. Lee, E. Bjornsson, A. Suzuki, 2010, Drug safety.

S1002 Co-Medication with Adrenoreceptor Antagonists Is Associated with Lower MELD Scores At Admission in Patients with Acetaminophen-Induced Acute Liver Failure

William M. Lee, P. Watkins, A. Suzuki, 2009 .

Characterizing phenotypes and outcomes of drug‐associated liver injury using electronic medical record data

A. Suzuki, C. Hunt, Julie I. Papay, 2013, Pharmacoepidemiology and drug safety.